Mackenzie Financial
PRVB

Mackenzie Financial’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Mackenzie Financial’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-57,141
Closed -$604K – 1638
2022
Q4 		$604K Buy
+57,141
New +$461K ﹤0.01% 869

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Mackenzie Financial's PRVB Position: Q1 2023 in Review

Mackenzie Financial sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 57,141 shares — an estimated $604K sold.

Mackenzie Financial first reported a position in PRVB in Q4 2022 and held it in 1 quarter. The position peaked at $604K in Q4 2022. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

  • Mackenzie Financial reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Mackenzie Financial sold 57,141 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $604K.
  • Mackenzie Financial first reported a position in Provention Bio, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Mackenzie Financial's Provention Bio, Inc. Common Stock position peaked at $604K in Q4 2022.
  • 182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on Mackenzie Financial's 13F filing for Q1 2023, filed 24 Apr 2023.